PUBLISHER: DelveInsight | PRODUCT CODE: 1108673
PUBLISHER: DelveInsight | PRODUCT CODE: 1108673
Retinal Vein Occlusion - Epidemiology Forecast - 2032
DelveInsight's, 'Retinal vein occlusion (RVO) - Epidemiology Forecast-2032' report delivers an in-depth understanding of Retinal vein occlusion, historical and forecasted epidemiology as well as Retinal vein occlusion trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Retinal vein occlusion Understanding
Retinal vein occlusion is one of the most frequently occurring retinal vascular disorders in elderly patients that develop predominantly in individuals over the age of 65 years. The main risk factor for Retinal vein occlusion includes age. With the increase of the geriatric population, as of now, the prevalence of retinal vein occlusion is also supposed to be on the high rise. Further risk factors include systemic conditions like hypertension, arteriosclerosis, diabetes mellitus, hyperlipidemia, cerebral vascular stroke, blood hyperviscosity, and thrombophilia. A strong risk factor for Retinal vein occlusion is metabolic syndrome (hypertension, diabetes mellitus, and hyperlipidemia). Individuals with end-organ damage caused by diabetes mellitus and hypertension have a substantially increased risk for retinal vein occlusion. Ophthalmic risk factors for Retinal vein occlusion are ocular hypertension and glaucoma, higher ocular perfusion pressure, and changes in the retinal arteries.
Retinal vein occlusion is categorized into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) according to the site of blockage in the retinal vein. CRVO is divided further into nonischemic and ischemic types according to the perfusion status based on fluorescein angiography. BRVO consists of major branch retinal vein occlusion (when one of the major branch retinal veins is occluded, usually near, or rarely at, the optic disc) and macular branch retinal vein occlusion (when only one of the macular venules is occluded).
The primary symptom of retinal vein occlusion is a sudden vision change. It could include a blurry vision or a partial or complete loss of vision. Mostly persistent bruising and swelling of the macula is associated with permanent loss of central vision. This swelling is caused by damaged blood vessels that leak fluid. These symptoms usually occur in one eye and are often painless and could be short-term or permanent, depending on how quickly the patient seeks treatment and other health conditions. Macular edema is the major complication of significant visual loss in patients with CRVO and BRVO, and various treatments have been used to improve macular edema and cause regression of intraocular neovascularization.
Retinal vein occlusion Diagnosis
The initial examination of a patient with Retinal vein occlusion includes a comprehensive adult medical eye evaluation, with particular attention to those aspects related to retinal vascular disease. Several tests are being used for the diagnosis of Retinal vein occlusion such as Optical coherence tomography (OCT), and Fluorescein angiography (FA). Apart from this, Systemic evaluation is often performed in patients with CRVO and is directed by the patient's age, coexisting risk factors, and medical history.
Continued in the report…..
Retinal vein occlusion Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Retinal vein occlusion, Total Diagnosed Prevalent Cases of Retinal vein occlusion, Gender-specific Diagnosed Prevalent Cases of Retinal vein occlusion, Age-specific Diagnosed Prevalent Cases of Retinal vein occlusion, and Type-specific Diagnosed Prevalent Cases of Retinal vein occlusion, the scenario of Retinal vein occlusion in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Retinal vein occlusion Detailed Epidemiology Segmentation
- In the year 2021, the total prevalent cases of Retinal vein occlusion were approximately 2,708,118 cases in the 7MM, which are expected to increase by 2032 at the CAGR of 1.0% during the study period (2019-2032).
- Among EU-5 countries, the highest number of prevalent cases of Retinal vein occlusion were in Germany, (approximately 225,397 cases), in the year 2021, which are expected to increase by 2032. The lowest number of cases were observed in Spain.
- In 2021, the total diagnosed prevalent cases of Retinal vein occlusion in the 7MM were approximately 1,518,208 cases which are estimated to increase by 2032.
- In the 7MM, total gender-specific diagnosed prevalent cases of Retinal vein occlusion were approximately 715,167 cases for males and 803,041 cases for females in the year 2021. As per the analysis, these cases are expected to increase by the year 2032.
- Retinal vein occlusion is more frequent in the older age population. The age-specific diagnosed prevalent cases in the 7MM were approximately 454,378, 572,552, and 491,279 cases for the age group less than 65 years, 65-74 years, and ≥75 years, in 2021.
- In the 7MM, total type-specific diagnosed prevalent cases of Retinal vein occlusion were approximately 298,789 cases for CRVO and 1,219,419 cases for BRVO in the year 2021. As per the analysis, these cases are expected to increase by the year 2032.
Scope of the Report:
- The report covers a descriptive overview of Retinal vein occlusion, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the US, EU5 countries (Germany, France, Italy, Spain, and the UK), and Japan.
- The report assesses the disease risk and burden of Retinal vein occlusion.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for the 7MM, total prevalent cases of Retinal vein occlusion, total diagnosed prevalent cases of Retinal vein occlusion, gender-specific diagnosed prevalent cases of Retinal vein occlusion, age-specific diagnosed prevalent cases of Retinal vein occlusion, and type-specific diagnosed prevalent cases of Retinal vein occlusion.
Report Highlights:
- 11-Year Forecast of Retinal vein occlusion
- The 7MM Coverage
- Total Prevalent Cases of Retinal vein occlusion
- Total Diagnosed Prevalent Cases of Retinal vein occlusion
- Gender-specific Diagnosed Prevalent Cases of Retinal vein occlusion
- Age-specific Diagnosed Prevalent Cases of Retinal vein occlusion
- Type-specific Diagnosed Prevalent Cases of Retinal vein occlusion
Key Questions Answered
- What are the disease risk and burdens of Retinal vein occlusion?
- What is the historical Retinal vein occlusion patient pool in the US, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Retinal vein occlusion at the 7MM level?
- What will be the growth opportunities across the 7MM concerning the patient population with Retinal vein occlusion?
- Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Retinal vein occlusion during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to buy:
The Retinal vein occlusion report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Retinal vein occlusion epidemiology forecast.
- The Retinal vein occlusion epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
- The Retinal vein occlusion epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Table of Contents
1. Key Insights
2. Report Introduction
3. RVO Epidemiology Overview at a Glance
- 3.1. Patient Share (%) Distribution of RVO in 2019
- 3.2. Patient Share (%) Distribution of RVO in 2032
4. Executive Summary of RVO
5. Disease Background and Overview
- 5.1. Introduction to RVO
- 5.2. Signs and Symptoms
- 5.3. Causes and Risk Factors
- 5.4. Pathophysiology
- 5.5. Diagnosis of RVO
- 5.5.1. Optical Coherence Tomography
- 5.5.2. Fluorescein angiography
- 5.5.3. Systemic Evaluation
- 5.5.4. Optical coherence tomography angiography (OCTA)
- 5.5.5. Fundus Autofluorescence
- 5.5.6. Laboratory Tests
- 5.5.7. Diagnostic Guideline
- 5.5.7.1. European Society of Retina Specialists Diagnostic Guidelines
6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Methodology of Epidemiology
- 6.3. Assumptions and Rationale: The 7MM
- 6.3.1. Prevalent Cases of RVO
- 6.3.2. Total Diagnosed Prevalent Cases of RVO
- 6.3.3. Gender-specific Diagnosed Prevalent Cases of RVO
- 6.3.4. Age-specific Diagnosed Prevalent Cases of RVO
- 6.3.5. Type-specific Diagnosed Prevalent Cases of RVO
- 6.3.6. Treated cases of RVO
- 6.4. Total Prevalent Cases of RVO in the 7MM
- 6.4.1. Total Diagnosed Prevalent Cases of RVO in the 7MM
- 6.5. The United States
- 6.5.1. Total Prevalent Cases of RVO in the US
- 6.5.2. Total Diagnosed Prevalent Cases of RVO in the US
- 6.5.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in the US
- 6.5.4. Total Age-specific Diagnosed Prevalent Cases of RVO in the US
- 6.5.5. Type-specific Diagnosed Prevalent Cases of RVO in the US
- 6.6. Major Five European Countries
- 6.6.1. Total Prevalent Cases of RVO in EU-5
- 6.6.2. Total Diagnosed Prevalent Cases of RVO in EU-5
- 6.6.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in EU-5
- 6.6.4. Total Age-specific Diagnosed Prevalent Cases of RVO in EU-5
- 6.6.5. Type-specific Diagnosed Prevalent Cases of RVO in EU-5
- 6.6.6. Germany
- 6.6.6.1. Total Prevalent Cases of RVO in Germany
- 6.6.6.2. Total Diagnosed Prevalent Cases of RVO in Germany
- 6.6.6.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in Germany
- 6.6.6.4. Total Age-specific Diagnosed Prevalent Cases of RVO in Germany
- 6.6.6.5. Type-specific Diagnosed Prevalent Cases of RVO in Germany
- 6.6.7. France
- 6.6.7.1. Total Prevalent Cases of RVO in France
- 6.6.7.2. Total Diagnosed Prevalent Cases of RVO in France
- 6.6.7.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in France
- 6.6.7.4. Total Age-specific Diagnosed Prevalent Cases of RVO in France
- 6.6.7.5. Type-specific Diagnosed Prevalent Cases of RVO in France
- 6.6.8. Italy
- 6.6.8.1. Total Prevalent Cases of RVO in Italy
- 6.6.8.2. Total Diagnosed Prevalent Cases of RVO in Italy
- 6.6.8.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in Italy
- 6.6.8.4. Total Age-specific Diagnosed Prevalent Cases of RVO in Italy
- 6.6.8.5. Type-specific Diagnosed Prevalent Cases of RVO in Italy
- 6.6.9. Spain
- 6.6.9.1. Total Prevalent Cases of RVO in Spain
- 6.6.9.2. Total Diagnosed Prevalent Cases of RVO in Spain
- 6.6.9.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in Spain
- 6.6.9.4. Total Age-specific Diagnosed Prevalent Cases of RVO in Spain
- 6.6.9.5. Type-specific Diagnosed Prevalent Cases of RVO in Spain
- 6.6.10. The UK
- 6.6.10.1. Total Prevalent Cases of RVO in the UK
- 6.6.10.2. Total Diagnosed Prevalent Cases of RVO in the UK
- 6.6.10.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in the UK
- 6.6.10.4. Total Age-specific Diagnosed Prevalent Cases of RVO in the UK
- 6.6.10.5. Type-specific Diagnosed Prevalent Cases of RVO in the UK
- 6.7. Japan
- 6.7.1. Total Prevalent Cases of RVO in Japan
- 6.7.2. Total Diagnosed Prevalent Cases of RVO in Japan
- 6.7.3. Total Gender-specific Diagnosed Prevalent Cases of RVO in Japan
- 6.7.4. Total Age-specific Diagnosed Prevalent Cases of RVO in Japan
- 6.7.5. Type-specific Diagnosed Prevalent Cases of RVO in Japan
7. Patient Journey
8. Appendix
- 8.1. Bibliography
- 8.2. Abbreviations
- 8.3. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables
- Table 1: Summary of RVO Epidemiology (2019-2032)
- Table 2: List of diagnostic tests in RVO
- Table 3: Total Prevalent Cases of RVO in the 7MM, in Thousands (2019-2032)
- Table 4: Total Diagnosed Prevalent Cases of RVO in the 7MM, in Thousands (2019-2032)
- Table 5: Total Prevalent Cases of RVO in the US, in Thousands (2019-2032)
- Table 6: Total Diagnosed Prevalent Cases of RVO in the US, in Thousands (2019-2032)
- Table 7: Total Gender-specific Diagnosed Prevalent Cases of RVO in the US, in Thousands (2019-2032)
- Table 8: Total Age-specific Diagnosed Prevalent Cases of RVO in the US, in Thousands (2019-2032)
- Table 9: Type-specific Diagnosed Prevalent Cases of RVO in the US, in Thousands (2019-2032)
- Table 10: Total Prevalent Cases of RVO in EU-5, in Thousands (2019-2032)
- Table 11: Total Diagnosed Prevalent Cases of RVO in EU-5, in Thousands (2019-2032)
- Table 12: Total Gender-specific Diagnosed Prevalent Cases of RVO in EU-5, in Thousands (2019-2032)
- Table 13: Total Age-specific Diagnosed Prevalent Cases of RVO in EU-5, in Thousands (2019-2032)
- Table 14: Type-specific Diagnosed Prevalent Cases of RVO in EU-5, in Thousands (2019-2032)
- Table 15: Total Prevalent Cases of RVO in Germany, in Thousands (2019-2032)
- Table 16: Total Diagnosed Prevalent Cases of RVO in Germany, in Thousands (2019-2032)
- Table 17: Total Gender-specific Diagnosed Prevalent Cases of RVO in Germany, in Thousands (2019-2032)
- Table 18: Total Age-specific Diagnosed Prevalent Cases of RVO in Germany, in Thousands (2019-2032)
- Table 19: Type-specific Diagnosed Prevalent Cases of RVO in Germany, in Thousands (2019-2032)
- Table 20: Total Prevalent Cases of RVO in France, in Thousands (2019-2032)
- Table 21: Total Diagnosed Prevalent Cases of RVO in France, in Thousands (2019-2032)
- Table 22: Total Gender-specific Diagnosed Prevalent Cases of RVO in France, in Thousands (2019-2032)
- Table 23: Total Age-specific Diagnosed Prevalent Cases of RVO in France, in Thousands (2019-2032)
- Table 24: Type-specific Diagnosed Prevalent Cases of RVO in France, in Thousands (2019-2032)
- Table 25: Total Prevalent Cases of RVO in Italy, in Thousands (2019-2032)
- Table 26: Total Diagnosed Prevalent Cases of RVO in Italy, in Thousands (2019-2032)
- Table 27: Total Gender-specific Diagnosed Prevalent Cases of RVO in Italy, in Thousands (2019-2032)
- Table 28: Total Age-specific Diagnosed Prevalent Cases of RVO in Italy, in Thousands (2019-2032)
- Table 29: Type-specific Diagnosed Prevalent Cases of RVO in Italy, in Thousands (2019-2032)
- Table 30: Total Prevalent Cases of RVO in Spain, in Thousands (2019-2032)
- Table 31: Total Diagnosed Prevalent Cases of RVO in Spain, in Thousands (2019-2032)
- Table 32: Total Gender-specific Diagnosed Prevalent Cases of RVO in Spain, in Thousands (2019-2032)
- Table 33: Total Age-specific Diagnosed Prevalent Cases of RVO in Spain, in Thousands (2019-2032)
- Table 34: Type-specific Diagnosed Prevalent Cases of RVO in Spain, in Thousands (2019-2032)
- Table 35: Total Prevalent Cases of RVO in the UK, in Thousands (2019-2032)
- Table 36: Total Diagnosed Prevalent Cases of RVO in the UK, in Thousands (2019-2032)
- Table 37: Total Gender-specific Diagnosed Prevalent Cases of RVO in the UK, in Thousands (2019-2032)
- Table 38: Total Age-specific Diagnosed Prevalent Cases of RVO in the UK, in Thousands (2019-2032)
- Table 39: Type-specific Diagnosed Prevalent Cases of RVO in the UK, in Thousands (2019-2032)
- Table 40: Total Prevalent Cases of RVO in Japan, in Thousands (2019-2032)
- Table 41: Total Diagnosed Prevalent Cases of RVO in Japan, in Thousands (2019-2032)
- Table 42: Total Gender-specific Diagnosed Prevalent Cases of RVO in Japan, in Thousands (2019-2032)
- Table 43: Total Age-specific Diagnosed Prevalent Cases of RVO in Japan, in Thousands (2019-2032)
- Table 44: Type-specific Diagnosed Prevalent Cases of RVO in Japan, in Thousands (2019-2032)
- Table 45: Abbreviations used in the Report
List of Figures
- Figure 1: Retinal vein occlusion
- Figure 2: CRVO with hemorrhage
- Figure 3: Branch Retinal vein occlusion
- Figure 4: Signs and Symptoms of RVO
- Figure 5: Causes and risk factors of RVO
- Figure 6: Pathophysiology of RVO
- Figure 7: Optical coherence tomography
- Figure 8: Fluorescein angiography
- Figure 9: Fundus autofluorescence
- Figure 10: Total Prevalent Cases of RVO in the 7MM (2019-2032)
- Figure 11: Total Diagnosed Prevalent Cases of RVO in the 7MM (2019-2032)
- Figure 12: Total Prevalent Cases of RVO in the US (2019-2032)
- Figure 13: Total Diagnosed Prevalent Cases of RVO in the US (2019-2032)
- Figure 14: Total Gender-specific Diagnosed Prevalent Cases of RVO in the US (2019-2032)
- Figure 15: Total Age-specific Diagnosed Prevalent Cases of RVO in the US (2019-2032)
- Figure 16: Type-specific Diagnosed Prevalent Cases of RVO in the US (2019-2032)
- Figure 17: Total Prevalent Cases of RVO in EU-5 (2019-2032)
- Figure 18: Total Diagnosed Prevalent Cases of RVO in EU-5 (2019-2032)
- Figure 19: Total Gender-specific Diagnosed Prevalent Cases of RVO in EU-5 (2019-2032)
- Figure 20: Total Age-specific Diagnosed Prevalent Cases of RVO in EU-5 (2019-2032)
- Figure 21: Type-specific Diagnosed Prevalent Cases of RVO in EU-5 (2019-2032)
- Figure 22: Total Prevalent Cases of RVO in Germany (2019-2032)
- Figure 23: Total Diagnosed Prevalent Cases of RVO in Germany (2019-2032)
- Figure 24: Total Gender-specific Diagnosed Prevalent Cases of RVO in Germany (2019-2032)
- Figure 25: Total Age-specific Diagnosed Prevalent Cases of RVO in Germany (2019-2032)
- Figure 26: Type-specific Diagnosed Prevalent Cases of RVO in Germany (2019-2032)
- Figure 27: Total Prevalent Cases of RVO in France (2019-2032)
- Figure 28: Total Diagnosed Prevalent Cases of RVO in France (2019-2032)
- Figure 29: Total Gender-specific Diagnosed Prevalent Cases of RVO in France (2019-2032)
- Figure 30: Total Age-specific Diagnosed Prevalent Cases of RVO in France (2019-2032)
- Figure 31: Type-specific Diagnosed Prevalent Cases of RVO in France (2019-2032)
- Figure 32: Total Prevalent Cases of RVO in Italy (2019-2032)
- Figure 33: Total Diagnosed Prevalent Cases of RVO in Italy (2019-2032)
- Figure 34: Total Gender-specific Diagnosed Prevalent Cases of RVO in Italy (2019-2032)
- Figure 35: Total Age-specific Diagnosed Prevalent Cases of RVO in Italy (2019-2032)
- Figure 36: Type-specific Diagnosed Prevalent Cases of RVO in Italy (2019-2032)
- Figure 37: Total Prevalent Cases of RVO in Spain (2019-2032)
- Figure 38: Total Diagnosed Prevalent Cases of RVO in Spain (2019-2032)
- Figure 39: Total Gender-specific Diagnosed Prevalent Cases of RVO in Spain (2019-2032)
- Figure 40: Total Age-specific Diagnosed Prevalent Cases of RVO in Spain (2019-2032)
- Figure 41: Type-specific Diagnosed Prevalent Cases of RVO in Spain (2019-2032)
- Figure 42: Total Prevalent Cases of RVO in the UK (2019-2032)
- Figure 43: Total Diagnosed Prevalent Cases of RVO in the UK (2019-2032)
- Figure 44: Total Gender-specific Diagnosed Prevalent Cases of RVO in the UK (2019-2032)
- Figure 45: Total Age-specific Diagnosed Prevalent Cases of RVO in the UK (2019-2032)
- Figure 46: Type-specific Diagnosed Prevalent Cases of RVO in the UK (2019-2032)
- Figure 47: Total Prevalent Cases of RVO in Japan (2019-2032)
- Figure 48: Total Diagnosed Prevalent Cases of RVO in Japan (2019-2032)
- Figure 49: Total Gender-specific Diagnosed Prevalent Cases of RVO in Japan (2019-2032)
- Figure 50: Total Age-specific Diagnosed Prevalent Cases of RVO in Japan (2019-2032)
- Figure 51: Type-specific Diagnosed Prevalent Cases of RVO in Japan (2019-2032)
- Figure 52: Patient Journey
